little as 400 mg weekly up to 800 mg daily. In addition, the assessment of drug efficacy is complicated by the long elimination half life (t½) which is usually 30 to 60 days but which may be much greater particularly in obese patients. Evaluation of symptoms and electrocardiographic monitoring do not permit differentiations of drug failure from the need for additional amiodarone, nor do they identify those patients in whom arrhythmia may be controlled with less amiodarone. A clinical marker of drug efficacy is needed to help determine when to increase dosage if arrhythmia persists and when to decrease when arrhythmia is controlled.
The demonstration by Debbas and pointes. In the majority, however, measurement of the QT interval is not a useful guide to the identification of those who may benefit from alteration in dosage, and from the present work3 one may achieve success in a maximum of one third of patients.
Others have suggested that reverse triiodothyronine levels are useful in monitoring efficacy and side effects. 6 Amiodarone inhibits the peripheral conversion of thyroxine to triiodothyronine in favour of reverse triiodothyronine. During chronic treatment most patients will show an increase in thyroxine, a normal or low T3, and an increase in reverse T3 unaccompanied by alteration in thyroid state. Though an approximate therapeutic as well as toxic range of reverse T3 has been determined in a small group of patients who experienced suppression of arrhythmia during amiodarone, the role of this measurement in relation to dosage changes remains to be defined.
Because it is influenced by stress, concurrent illness, and thyroid disease, reverse triiodothyronine will possibly not prove the reliable index we seek. In our investigations measurement of plasma drug concentrations has provided a valuable guide to the appropriateness and magnitude of dosage changes. Though a specific therapeutic range remains to be determined control of arrhythmias is most often achieved with plasma amiodarone and desethylamiodarone concentrations of 1.5 ,ug/ml or less whereas higher levels are associated with an increased incidence of unwanted effects.7 Thus when arrhythmia is controlled with low plasma concentrations it may be appropriate to reduce the daily dose by a small amount while a larger reduction is indicated when plasma levels are high. When arrhythmia is not controlled a low plasma level suggests reduced bioavailability and the requirement for an increased dose, while high plasma levels indicate the need for additional or alternative therapy. During long term amiodarone treatment of patients with hypertrophic cardiomyopathy and refractory arrhythmia incremental dosage changes were guided by electrocardiographic monitoring and measurement of plasma amiodarone concentrations; in striving to achieve the lowest effective maintenance dose serious side effects were rare and only one of 53 patients stopped taking amiodarone.8 This approach is feasible in the management of arrhythmias which are not highly malignant. Though the principle of achieving the lowest effective dose is equally valid, alternative methods are necessary in patients with ventricular tachycardia which is prone to degenerate to fibrillation or which has been associated with impaired consciousness. The role of programmed electrical stimulation in this regard has been extensively explored but is confused by confficting results from major centres.9-"' Though the inducibility of ventricular tachycardia is not a predictor of subsequent efficaCy,12 13 the characteristics of the arrhythmia may be so.9 10 At present then there is no adequate single measurement to guide alterations in treatment. The findings of Debbas et al indicate that in a pure group changes in the QT interval may be of clinical value. 3 The strong correlation of plasma and myocardial amiodarone concentrations which they demonstrated suggests that plasma levels reflect myocardial impregnation and that when they are available they may be useful in guiding treatment. 
